Multiple Myeloma Research Foundation - MMRF
George Mulligan is a seasoned expert in translational medicine and oncology with extensive experience in leading scientific teams and developing biomarker strategies. Currently serving as Chief Scientific Officer at the Multiple Myeloma Research Foundation since March 2022, George has held previous positions including Chief Development Officer at Bantam Pharmaceutical and Chief Scientific Officer at Mitobridge, Inc. Between 2007 and 2015, George contributed to Takeda as Senior Director of Translational Medicine, where responsibilities included overseeing biomarker clinical strategies for key oncology drugs. With a strong educational background, including a PhD in Cellular and Developmental Biology from the State University of New York at Stony Brook and post-doctoral studies at MIT Center for Cancer Research, George possesses a robust foundation in cancer research and development.
This person is not in any teams
This person is not in any offices
Multiple Myeloma Research Foundation - MMRF
We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.